179 related articles for article (PubMed ID: 21263154)
1. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
2. Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
Nguyen TTT; Tamai M; Harama D; Kagami K; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Int J Hematol; 2022 Oct; 116(4):534-543. PubMed ID: 35524023
[TBL] [Abstract][Full Text] [Related]
3. Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
Fan S; Wang L; Lu Y; Li Z
Ann Hematol; 2024 Feb; 103(2):525-532. PubMed ID: 37940719
[TBL] [Abstract][Full Text] [Related]
4.
Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
[TBL] [Abstract][Full Text] [Related]
5. Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.
Gazeau N; Derrieux C; Nibourel O; Berthon C; Grardel N; Goursaud L; Boyer T; Dumezy F; Coiteux V; Quesnel B; Preudhomme C; Roche-Lestienne C; Duployez N
Leukemia; 2020 Aug; 34(8):2230-2233. PubMed ID: 31988437
[No Abstract] [Full Text] [Related]
6. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
Pui CH; Roberts KG; Yang JJ; Mullighan CG
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.
Zhou KI; Lin C; Neff JL; Galal A
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37197831
[TBL] [Abstract][Full Text] [Related]
8. Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.
Wang F; Li Y; Yang Z; Cao W; Liu Y; Zhao L; Zhang T; Zhao C; Yu J; Yu J; Zhou J; Zhang X; Li PP; Han M; Feng S; Ng BW; Hu ZW; Jiang E; Li K; Cui B
Nat Commun; 2024 Jan; 15(1):203. PubMed ID: 38172124
[TBL] [Abstract][Full Text] [Related]
9. Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a
Zahid MF; Kainthla R
Leuk Lymphoma; 2024 Jan; 65(1):123-127. PubMed ID: 37812134
[No Abstract] [Full Text] [Related]
10. Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.
Chuah C; Melo JV
Onco Targets Ther; 2009 Feb; 2():83-94. PubMed ID: 20616897
[TBL] [Abstract][Full Text] [Related]
11. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism.
Leow BCS; Kok CH; Yeung DT; Hughes TP; White DL; Eadie LN
Sci Rep; 2023 Aug; 13(1):13110. PubMed ID: 37567965
[TBL] [Abstract][Full Text] [Related]
12. Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.
Li Y; Yang X; Sun Y; Li Z; Yang W; Ju B; Easton J; Pei D; Cheng C; Lee S; Pui CH; Yu J; Chi H; Yang JJ
Blood; 2022 Sep; 140(13):1507-1521. PubMed ID: 35675514
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity.
Koller P; Baran N; Harutyunyan K; Cavazos A; Mallampati S; Chin RL; Jiang Z; Sun X; Lee HH; Hsu JL; Williams P; Huang X; Curran MA; Hung MC; Konopleva M
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793852
[TBL] [Abstract][Full Text] [Related]
14. Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.
Tracy SI; Venkatesh H; Hekim C; Heltemes-Harris LM; Knutson TP; Bachanova V; Farrar MA
Blood; 2022 Jul; 140(4):335-348. PubMed ID: 35275990
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D levels do not cause vitamin-drug interactions with dexamethasone or dasatinib in mice.
Annu K; Yasuda K; Caufield WV; Freeman BB; Schuetz EG
PLoS One; 2021; 16(10):e0258579. PubMed ID: 34669728
[TBL] [Abstract][Full Text] [Related]
16. Repurposing anthelmintic agents to eradicate resistant leukemia.
Mezzatesta C; Abduli L; Guinot A; Eckert C; Schewe D; Zaliova M; Vinti L; Marovca B; Tsai YC; Jenni S; Aguade-Gorgorio J; von Stackelberg A; Schrappe M; Locatelli F; Stanulla M; Cario G; Bourquin JP; Bornhauser BC
Blood Cancer J; 2020 Jun; 10(6):72. PubMed ID: 32591499
[TBL] [Abstract][Full Text] [Related]
17. Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas.
Uckun FM; Qazi S
Cancer Drug Resist; 2018; 1():30-47. PubMed ID: 31788667
[TBL] [Abstract][Full Text] [Related]
18. Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance.
Eyler CE; Matsunaga H; Hovestadt V; Vantine SJ; van Galen P; Bernstein BE
Genome Biol; 2020 Jul; 21(1):174. PubMed ID: 32669109
[TBL] [Abstract][Full Text] [Related]
19. Treatment for a primary multidrug-resistant B-cell acute lymphoblastic leukemia patient carrying a SSBP2-CSF1R fusion gene: a case report.
Wang H; Wang Y; Hao L; Liu X; Zhang J; Yao P; Liu D; Wang R
Front Oncol; 2023; 13():1291570. PubMed ID: 38107066
[TBL] [Abstract][Full Text] [Related]
20. Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.
Kaserer T; Blagg J
Cell Chem Biol; 2018 Nov; 25(11):1359-1371.e2. PubMed ID: 30146241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
